Equities

Autonomix Medical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AMIX:NAQ

Autonomix Medical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.40
  • Today's Change0.002 / 0.40%
  • Shares traded12.02k
  • 1 Year change-85.19%
  • Beta--
Data delayed at least 15 minutes, as of Feb 09 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.

  • Revenue in USD (TTM)0.00
  • Net income in USD-16.69m
  • Incorporated2014
  • Employees8.00
  • Location
    Autonomix Medical Inc21 Waterway Ave, Suite 300THE WOODLANDS 77380United StatesUSA
  • Phone+1 (832) 277-7816
  • Websitehttps://autonomix.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aethlon Medical Inc0.00-11.26m2.17m9.00--0.2955-----56.69-56.690.007.550.00----0.00-139.25-86.44-181.09-98.06-------3,662.04----0.00-------9.67------
Tivic Health Systems Inc482.00k-7.51m2.30m7.00--0.271--4.77-9.87-9.870.59143.360.10022.0734.4368,857.14-156.00-118.40-178.18-148.80-58.095.50-1,557.26-610.995.86--0.00---33.6713.1831.40------
Agape ATP Corp1.48m-2.71m2.45m16.00--0.1071--1.65-0.2994-0.29940.05230.45660.104713.9960.1492,806.88-19.46-34.76-21.27-44.4452.6869.19-185.74-92.8616.18--0.0056---7.57---17.53------
INVO Fertility Inc6.94m-27.13m2.64m28.00------0.3798-602.89-644.6750.028.630.387419.5026.14247,996.40-149.96-63.14-299.48-98.9639.1760.46-387.11-276.300.1022-10.360.2530--116.2534.57-16.33--9.88--
Work Medical Technology Group Ltd10.74m-3.71m2.67m229.00--0.0002--0.2489-2,871.58-2,871.587,811.598,868.19------46,903.67--------26.89---35.42--0.9802-8.870.4505---15.18---3,217.31------
Autonomix Medical Inc0.00-16.69m2.76m8.00--0.3844-----5.08-5.080.001.040.00----0.00-250.94---316.15--------------0.00------26.03------
Fuse Medical Inc18.40m3.63m2.96m31.001.11--0.80140.16060.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Avalon Globocare Corp1.40m-18.76m3.01m5.00------2.16-9.75-9.750.6074-1.100.0974--16.92279,216.00-131.94-76.04-1,379.37-114.3725.7023.19-1,355.20-888.890.1477-4.072.69--6.19-2.9252.69------
Encision Inc6.30m-380.94k3.19m22.00--1.71--0.5061-0.0284-0.02840.50570.11051.662.277.98286,353.60-10.05-3.17-14.19-4.4052.6451.47-6.05-2.010.9127-5.690.1094---0.464-3.0968.17--8.09--
Catheter Precision Inc730.00k-22.19m3.22m22.00--0.4687--4.41-37.38-37.380.93714.120.0281.646.3533,181.82-66.93-128.03-78.29-160.1292.60-242.70-2,393.84-15,268.880.4569-66.840.0449---4.98-19.8969.45---24.21--
ENvue Medical Inc2.69m-5.21m3.54m15.00--0.0774--1.32-83.93-83.937.4642.000.09090.83646.45179,000.00-25.01-97.63-32.90-149.1830.0253.04-275.12-397.830.6675--0.0669--12.0537.000.1617------
Vycor Medical Inc1.90m-338.88k3.67m7.00------1.93-0.0103-0.01030.0548-0.12061.891.576.73271,678.60-1.44-36.90----85.3589.43-0.7625-26.120.10280.8609----8.812.67-11.32---40.90--
Profusa Inc0.00-39.09m3.89m0.00---------278.73-278.730.00-61.050.00-------599.88-----------------14.56---------849.77------
Reflect Scientific Inc1.72m-29.42k3.99m7.00--1.9221.352.32-0.0004-0.00040.02010.02430.68260.84298.78245,945.70-1.1711.10-1.3213.2158.4762.48-1.7110.009.46--0.00---47.09-6.99-613.46------
Data as of Feb 09 2026. Currency figures normalised to Autonomix Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

3.10%Per cent of shares held by top holders
HolderShares% Held
Mariner LLCas of 30 Sep 2025100.64k1.46%
Two Sigma Securities LLCas of 30 Sep 202525.02k0.36%
BMO Asset Management, Inc.as of 30 Sep 202525.00k0.36%
Ikarian Capital LLCas of 30 Sep 202520.00k0.29%
XTX Markets LLCas of 30 Sep 202514.10k0.20%
Warberg Asset Management LLCas of 30 Sep 202511.33k0.16%
Geode Capital Management LLCas of 30 Sep 202510.15k0.15%
Tower Research Capital LLCas of 30 Sep 20255.34k0.08%
PNC Bank, NA (Investment Management)as of 31 Dec 20251.59k0.02%
Arax Advisory Partnersas of 30 Jun 20251.00k0.01%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.